BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/05/25
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/04/25
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/04/25
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the StockZacks Investment Research • 07/31/25
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in DecemberGlobeNewsWire • 07/31/25
BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 07/28/25
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National SummitGlobeNewsWire • 07/09/25
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 07/07/25
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate DevelopmentGlobeNewsWire • 07/07/25
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 MillionGlobeNewsWire • 06/27/25
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 06/25/25
5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid VolatilityZacks Investment Research • 06/25/25
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACIGlobeNewsWire • 06/16/25
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European CountriesGlobeNewsWire • 06/06/25
BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 06/04/25
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical ImmunologyGlobeNewsWire • 06/02/25
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All AgesGlobeNewsWire • 05/30/25
Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to TradeZacks Investment Research • 05/26/25
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)GlobeNewsWire • 05/16/25